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Osteoporosis-related fractures are a major public health problem and one in two women and one in four men are aﬀected with
osteoporosis-related fractures. Alendronate (Fosamax) is one of the ﬁrst bisphosphonates used to treat osteoporosis eﬀectively.
Recently, however, there is a concern regarding long bone insuﬃciency fractures related to long-term alendronate therapy. We
report a case of bilateral femoral insuﬃciency fractures likely related to long-term alendronate therapy, the classic symptoms,
signs,and treatment of these fractures.
1.Introduction
Osteoporosis-related fractures are a major public health
problem mainly in postmenopausal women and the elderly.
Osteoporosis aﬀects an estimated of 75 million people in
Europe, United States of America, and Japan [1]. There
are several treatment options available including calcium,
vitamin D, parathyroid hormone, strontium, and bispho-
sphonates. Since their introduction, bisphosphonates have
been widely used in osteoporotic treatment. Alendronate
(Fosamax, Merck & company, inc.) is one of the ﬁrst
bisphosphonates to be licensed and used. There are several
studies showing the beneﬁts of alendronate and other
bisphosphonates. Recently, however, there is an emerging
concern regarding long bone stress fractures secondary to
long-term alendronate intake. We present a case of bilateral
femoral shaft insuﬃciency fractures secondary to long-term
alendronate therapy.
2.CaseReport
A 74-year-old lady presented to orthopaedic clinic with
a four-month history of bilateral thigh pain. She had no
history of trauma. She had history of breast cancer treated
with lumpectomy 10 years ago and has a history of well-
controlled asthma, for which she did not require corticos-
teroidtreatment.Shehadbeenreceiving alendronatetherapy
for postmenopausal osteoporosis for 10 years. Radiographs
revealed lateral cortical thickening of the mid-diaphysis of
both femurs (Figure 1). The patient underwent a bone
scan to rule out the possibility of metastases due to her
previous history. The bone scan raised the possible diagnosis
of a healing stress fracture. Computed tomography scan
conﬁrmed a stress fracture (Figure 2). She was given the
advice of protective weight bearing and planned followup.
Four days after consultation, she tripped and sustained
a transverse fracture of the left femur and underwent
uneventful femoral intramedullary nailing (Figures 3(a)
and 3(b)). An endocrinology consultation was sought, and
alendronate therapy was stopped. Bone mineral density
scan was organized, and she was started on teriparatide
treatment. Because there was no progressive right thighpain,
no further surgical management was oﬀered beyond close
followup. At four months postoperatively, the left femur
fracture showed good radiological union (Figure 3(c)).
There was still persistent pain in the right femur and a
deﬁnite linear lucency in the lateral femoral cortex on plain
radiographs. She underwent prophylactic intramedullary2 Journal of Osteoporosis
Figure 1: Radiograph of both femurs showing stress fracture and lateral cortical thickening.
nailing of the right femur and had eventual complete relief
of her symptoms.
3.Discussion
The lifelong risk of having a fracture related to osteoporosis
is one in two for women and one in four for men. Prevention
and treatment of osteoporosis is a major public health
concern. Bisphosphonates have been widely used for treat-
ment of osteoporosis. They are antiresorptive agents which
act via inhibition of osteoclasts. As a consequence, bone
formationcoupledtoresorptionisalsodecreasedresultingin
an overall reduction of bone remodelling. Bisphosphonates
also combine with calcium and become incorporated in the
crystal structure of bone and retained within the skeletonfor
long periods of time. Therefore, they have the potential to
exert eﬀorts long after the treatment has been discontinued.
Alendronate is the ﬁrst bisphosphonate to be approved
for the treatment and prevention of osteoporosis. Several
previous studies have shown that alendronate reduces the
risk of osteoporotic fractures and osseous resorption in high
turnover bone disease. It has an excellent beneﬁt to risk
ratio for women with osteoporosis when used for 3-5 years.
However, the beneﬁt of continuing beyond ﬁve years is not
established.
In addition to other well-known side eﬀects of bisphos-
phonates, there is a recent concern regarding the association
of cortical insuﬃciency fractures and low-energy femoral
fractures with long-term alendronate use. Several published
case series and case reports suggest femoral shaft, and
subtrochanteric femur fractures can be associated with long-
term alendronate use [2–4]. Lenart et al. have shown a
signiﬁcant proportion of patients, in their study of low-
energysub-trochantericanddiaphysealfemurfractures,were
on long-term bisphosphonates. Clinical and radiological
features are almost unique in all of these reports [2]. The
characteristic features include prodromal pain in the thigh
for several months prior to the fracture (76% of the reported
cases), bilateral fractures eith e rs e q u e n t i a lo rs i m u l t a n e o u s ,
andfractureswith trivial trauma.The radiologicalfeaturesof
these fractures are lateral cortical thickening,cortical spiking
or beaking over the medial cortex, and transverse or short
oblique fractures.
Neviaser et al. reported in their study that 19 of the
25 patients on alendronate demonstrate a simple transverse
fracture with a unicortical beak in an area of cortical
hypertrophy. In contrast, this fracture pattern was seen in
onlyonepatientwho wasnotbeingtreatedwith alendronate,
indicating that the fracture pattern is typical in alendronateJournal of Osteoporosis 3
Figure 2: Computed tomography reveals bilateral femoral stress fractures.
(a) (b) (c)
Figure 3: Fracture left femur at the level of stress fracture site, immediate postoperative, and three months postoperative radiographs.
users [3]. Our patient also presented with these classic
symptoms and radiological signs.
Femoral insuﬃciency fractures after prolonged alen-
dronate therapy seldom heal spontaneously. Alendronate
acts as a strong inhibitor of osteoclastic bone resorption
which reduces the overall bone turnover. This has a
negative eﬀect on bone healing and is likely one of the
reasons why many of the insuﬃciency fractures have delayed
healing. Since alendronate inhibits osteoclastic remodeling,
endochondral fracture repair is the preferred method of
fracture healing. Intramedullary reconstruction with full-
length nails accomplishes this goal and protects the entire
femur. Locking plates preclude endochondral repair and are
not recommended as themethod ofﬁxation [4]. Sayed-Noor
and Sj¨ od´ en reported a case series of delayed union even
after internal ﬁxation of a femoral insuﬃciency fracture in
a patient who was on long-term alendronate [5]. Visekruna
et al. reported no radiographic evidence of union out as far
as22monthspostoperatively[6].CapeciandTejwani andHa
et al. reported union at an average of four and ﬁve months,
respectively, after internal ﬁxation [7, 8]. In our case, the left
femurfracture wastreated withareamed intramedullary nail
with union at four months. Because of the nonprogressive
pain from the right femur stress fracture, close observation
with protective weight-bearing was initially chosen but
proved to be insuﬃcient despite stopping alendronate. Ulti-
mately, prophylactic intramedullary nailing was performed
four months after with immediate symptom resolution. We4 Journal of Osteoporosis
support the view of Capeci and Tejwani and Ha et al. to treat
even the incomplete insuﬃciency fractures with internal
ﬁxation. As well, we feel clinicians should not be lured into
conservative management by the radiographic features of
focal cortical hypertrophy. Dietary calcium and vitamin D
status should be assessed, and adequate supplementation
should be prescribed. Teriparatide therapy can improve or
hasten healing of these fractures [6].
Although there is strong evidence supporting short-
term alendronate therapy to reduce the risk of osteoporotic
fractures, there is not enough evidence to suggest beneﬁt
in long-term use beyond ﬁve years. The continuation of
alendronate therapy after ﬁve years should be tailored to
individual patients after appropriate followup and the need
for ongoing therapy reassessed annually [4]. Any patients
with prodromal symptoms such as thigh pain should be
investigated with routine bilateral radiographs of the femur
looking for stress reaction, and if necessary, advanced
imaging-like bone scan or magnetic resonance imaging.
This is not the ﬁrst case report on insuﬃciency diaphyseal
fractures related to long-term alendronate therapy. However,
this is a case report with characteristic features and bilateral
involvement which highlights the importance of evaluating
patients on long-term alendronate therapy and recommends
early prophylactic internal ﬁxation of these fractures.
4.KeyPoints
(i) Long-term alendronate therapy is likely associated
with femoral insuﬃciency fractures.
(ii) Patients on more than 5 years of alendronate therapy
should be reevaluated annually regarding continua-
tion of treatment and need close observation.
(iii) Patients with thigh pain on alendronate therapy
should be investigated for femoral stress fractures.
(iv) Insuﬃciency fractures related to alendronate therapy
seldom heal without internal ﬁxation. Teriparatide
can hasten healing of these fractures.
5.ConﬂictofInterests
The authors declare that they have no conﬂict of interests.
References
[1] EFFO and NOF, “Who are candidates for prevention and
treatment for osteoporosis?” Osteoporosis International ,v o l .7 ,
no. 1, pp. 1–6, 1997.
[2] B.A.Lenart,A.S.Neviaser,S.Lymanet al.,“Associationoflow-
energy femoralfractures with prolonged bisphosphonate use: a
casecontrolstudy,” Osteoporosis International,v ol.20,no .8,p p .
1353–1362, 2009.
[3] A. S. Neviaser, S. K. Goh, J. S. Koh, F. Edobor-Osula, and D.
G. Lorich, “Low-energy femoral shaft fractures associated with
alendronate use,” Journal of Orthopaedic Trauma, vol. 22, no. 5,
pp. 346–350, 2008.
[ 4 ] E .S h a n e ,D .B u r r ,P .R .E b e l i n ge ta l . ,“ A t y p i c a ls u b t r o c h a n t e r i c
and diaphyseal femoral fractures: report of a task force of the
american society for bone and mineral Research,” Journal of
BoneandMineral Research,vol.25,no.11,pp.2267–2294,2010.
[ 5 ] A .S .S a y e d - N o o ra n dG .O .S j¨ od´ en, “Case reports: two femoral
insuﬃciency fractures after long-term alendronate therapy,”
Clinical Orthopaedics and Related Research, vol. 467, no. 7, pp.
1921–1926, 2009.
[6] M. Visekruna, D. Wilson, and F. E. McKiernan, “Severely sup-
pressed bone turnover and atypical skeletal fragility,” Journal of
Clinical Endocrinology and Metabolism,vol.93, no. 8,pp. 2948–
2952, 2008.
[7] C. M. Capeci and N. C. Tejwani, “Bilateral low-energy simulta-
neous or sequential femoral fractures in patients on long-term
alendronatetherapy,” Journalof BoneandJointSurgery. Series A,
vol. 91, no. 11, pp. 2556–2561, 2009.
[8] Y.-C. Ha, M.-R. Cho, K. H. Park, S.-Y. Kim, and K.-H. Koo,
“Is surgery necessary for femoral insuﬃciency fractures after
long-term bisphosphonate therapy?” Clinical Orthopaedics and
Related Research, vol. 468, no. 12, pp. 3393–3398, 2010.